Microarray analysis of bone marrow-derived macrophage cells treated with Kdo2-lipid A (KLA) and ATP

Search by fold change ratio | Search by KEGG pathway | Search by LIPID MAPS lipid pathway

Kdo2-Lipid A / ATP gene array data - treatment:control ratios

KEGG pathway: Renal cell carcinoma (mmu05211)

Legend:graph_icon: View data/graphs for replicates
Gene symbol    Time course plot Accession Description Treatment 15min 30min 1hr 2hr 4hr 8hr 20hr
AK050363
KLA  ATP  ATP+KLA
 AK050363 adult male liver tumor cDNA, RIKEN full-length enriched library, clone:C730040N22 product:unclassifiable, full insert sequence. [AK050363] KLA 1.00 .98 1.02 1.02 1.02 .92 .96
ATP .98 1.03 .93 .98 .96 1.02 .99
KLA/ATP 1.03 .96 .96 .95 1.02 .93 1.04
Akt1
KLA  ATP  ATP+KLA
 NM_009652 thymoma viral proto-oncogene 1 (Akt1), mRNA [NM_009652] KLA .80 .80 .75 .75 .71 .70 .82
ATP 1.00 1.02 .76 .85 .76 .68 .84
KLA/ATP .82 .80 .64 .68 .67 .61 .72
Akt2
KLA  ATP  ATP+KLA
 NM_007434 thymoma viral proto-oncogene 2 (Akt2), transcript variant 2, mRNA [NM_007434] KLA 1.45 1.49 1.81 1.61 1.83 1.17 .92
ATP 1.12 1.12 1.00 1.28 1.20 .94 1.06
KLA/ATP 1.48 1.70 1.69 1.58 1.57 1.32 1.27
Akt3
KLA  ATP  ATP+KLA
 NM_011785 thymoma viral proto-oncogene 3 (Akt3), mRNA [NM_011785] KLA 3.42 3.45 5.31 5.16 4.65 3.80 2.12
ATP 1.12 1.22 1.10 1.37 1.02 1.11 1.56
KLA/ATP 3.72 4.17 4.62 4.64 2.74 2.05 3.82
Araf
KLA  ATP  ATP+KLA
 NM_009703 v-raf murine sarcoma 3611 viral oncogene homolog (Araf), mRNA [NM_009703] KLA .87 .80 .89 .93 1.10 1.19 1.16
ATP 1.09 1.11 1.19 1.18 .78 .53 1.18
KLA/ATP 1.00 .95 .99 .93 .63 .55 1.27
Arnt
KLA  ATP  ATP+KLA
 AK037762 16 days neonate thymus cDNA, RIKEN full-length enriched library, clone:A130047M16 product:aryl hydrocarbon receptor nuclear translocator, full insert sequence. [AK037762] KLA 1.01 .87 .97 .92 1.13 .91 1.00
ATP 1.16 1.22 1.22 .84 1.57 1.19 1.05
KLA/ATP 1.06 1.06 1.08 .95 1.40 1.18 1.06
Arnt
KLA  ATP  ATP+KLA
 NM_001037737 aryl hydrocarbon receptor nuclear translocator (Arnt), transcript variant 1, mRNA [NM_001037737] KLA 1.23 1.27 1.32 1.23 1.34 1.33 1.30
ATP 1.02 1.09 .96 .90 .99 1.33 1.38
KLA/ATP 1.30 1.28 1.05 1.12 1.07 1.64 1.89
Arnt
KLA  ATP  ATP+KLA
 U14333 aromatic hydrocarbon receptor nuclear translocator Arnt (ARNT) mRNA, complete cds. [U14333] KLA 1.78 1.78 1.78 1.85 1.64 1.71 1.40
ATP .96 1.05 1.37 1.24 1.19 2.13 2.37
KLA/ATP 1.72 1.87 1.87 1.83 1.53 2.53 3.65
Arnt2
KLA  ATP  ATP+KLA
 NM_007488 aryl hydrocarbon receptor nuclear translocator 2 (Arnt2), mRNA [NM_007488] KLA 1.06 1.02 1.01 1.02 1.02 1.02 .97
ATP 1.00 1.00 1.03 1.05 .96 1.05 1.23
KLA/ATP .99 .97 .99 .99 1.05 1.08 1.29
BG242006
KLA  ATP  ATP+KLA
 BG242006 gb|602354740F1 NCI_CGAP_Mam1 Mus musculus cDNA clone IMAGE:4483064 5. [BG242006] KLA 2.25 2.23 2.26 2.70 2.56 2.67 1.45
ATP .92 .87 1.11 .97 .99 .97 .72
KLA/ATP 1.91 2.04 2.51 2.08 1.99 1.15 .67
Braf
KLA  ATP  ATP+KLA
 NM_139294 Braf transforming gene (Braf), mRNA [NM_139294] KLA 1.52 1.57 1.55 1.33 1.83 1.52 1.60
ATP 1.08 1.17 1.02 1.37 .95 1.15 .95
KLA/ATP 1.64 1.69 1.39 1.51 1.04 1.31 1.26
Cdc42
KLA  ATP  ATP+KLA
 NM_009861 cell division cycle 42 homolog (S. cerevisiae) (Cdc42), mRNA [NM_009861] KLA 1.04 1.01 1.02 1.04 1.12 1.21 1.12
ATP 1.07 1.10 1.04 1.06 1.02 .95 1.14
KLA/ATP .94 1.04 1.01 .97 .95 1.02 1.25
Crebbp
KLA  ATP  ATP+KLA
 AK048818 0 day neonate cerebellum cDNA, RIKEN full-length enriched library, clone:C230072N21 product:hypothetical protein, full insert sequence [AK048818] KLA 1.44 1.19 1.26 1.25 1.25 1.36 1.24
ATP .98 .90 1.04 1.11 1.95 2.72 1.51
KLA/ATP 1.17 1.27 1.45 1.28 1.98 2.80 2.52
Crebbp
KLA  ATP  ATP+KLA
 NM_001025432 CREB binding protein (Crebbp), mRNA [NM_001025432] KLA .97 1.01 .98 1.06 1.05 .99 1.07
ATP 1.07 1.05 .96 1.01 1.15 1.14 1.00
KLA/ATP 1.01 .97 .97 1.00 1.03 1.23 1.13
Crebbp
KLA  ATP  ATP+KLA
 S66385 gb|CREB-binding protein [mice, brain, mRNA Partial, 7326 nt]. [S66385] KLA 1.00 .98 1.08 .98 1.04 1.07 1.08
ATP .99 .98 .99 1.09 1.13 1.08 1.05
KLA/ATP 1.06 1.00 1.05 1.03 1.02 1.14 1.11
Crk
KLA  ATP  ATP+KLA
 NM_133656 v-crk sarcoma virus CT10 oncogene homolog (avian) (Crk), mRNA [NM_133656] KLA 1.29 1.32 1.41 1.38 1.75 1.59 1.52
ATP 1.08 1.17 1.01 .93 1.27 2.11 1.70
KLA/ATP 1.37 1.49 1.14 1.09 1.21 1.69 2.32
Crkl
KLA  ATP  ATP+KLA
 NM_007764 v-crk sarcoma virus CT10 oncogene homolog (avian)-like (Crkl), mRNA [NM_007764] KLA 1.85 1.97 2.08 1.73 1.66 1.64 1.36
ATP .97 .94 .78 .74 1.46 1.89 1.46
KLA/ATP 1.92 1.88 1.18 1.44 1.67 2.65 2.72
Cul2
KLA  ATP  ATP+KLA
 NM_029402 cullin 2 (Cul2), mRNA [NM_029402] KLA 2.33 2.37 2.43 1.90 1.34 1.10 1.09
ATP .98 .92 .98 .78 .73 .90 .76
KLA/ATP 2.27 2.19 1.86 1.53 1.07 .95 .81
Egln1
KLA  ATP  ATP+KLA
 NM_053207 EGL nine homolog 1 (C. elegans) (Egln1), mRNA [NM_053207] KLA .60 .60 .62 .54 .46 .48 .73
ATP 1.04 1.10 .94 1.00 .78 .84 .65
KLA/ATP .65 .64 .56 .53 .49 .47 .41
Egln2
KLA  ATP  ATP+KLA
 NM_053208 EGL nine homolog 2 (C. elegans) (Egln2), mRNA [NM_053208] KLA 1.12 1.22 1.40 1.55 1.86 1.39 1.19
ATP .94 .82 .61 .52 .74 1.26 1.29
KLA/ATP 1.11 1.04 .87 .73 1.28 1.53 1.54
Egln3
KLA  ATP  ATP+KLA
 NM_028133 EGL nine homolog 3 (C. elegans) (Egln3), mRNA [NM_028133] KLA .90 .90 .76 .73 .69 .83 1.38
ATP .96 1.03 .88 1.21 1.49 2.94 .90
KLA/ATP .88 .96 .78 .90 .98 1.18 1.15
Ep300
KLA  ATP  ATP+KLA
 AK042627 7 days neonate cerebellum cDNA, RIKEN full-length enriched library, clone:A730011L11 product:P300 TRANSCRIPTION COACTIVATOR (FRAGMENT) homolog [Mus sp], full insert sequence. [AK042627] KLA 1.02 .95 .92 1.04 1.01 1.00 1.05
ATP 1.06 .89 .88 .89 1.00 .90 1.07
KLA/ATP 1.10 1.02 .87 .91 1.04 .97 .98
Ep300
KLA  ATP  ATP+KLA
 NM_177821 E1A binding protein p300 (Ep300), mRNA [NM_177821] KLA 1.61 1.26 1.57 1.38 1.78 1.41 1.40
ATP 1.34 1.60 1.11 1.08 1.16 1.05 1.15
KLA/ATP 1.86 1.94 1.18 1.56 1.71 1.42 2.05
Epas1
KLA  ATP  ATP+KLA
 AK087208 0 day neonate lung cDNA, RIKEN full-length enriched library, clone:E030034H04 product:endothelial PAS domain protein 1, full insert sequence. [AK087208] KLA .92 .91 .87 .93 1.01 .85 .83
ATP 1.02 1.12 1.03 1.29 1.23 1.12 .88
KLA/ATP .85 .85 1.05 1.23 1.14 .93 .81
Epas1
KLA  ATP  ATP+KLA
 NM_010137 endothelial PAS domain protein 1 (Epas1), mRNA [NM_010137] KLA 1.12 1.03 1.19 1.00 1.00 1.02 .99
ATP 1.09 1.03 .96 .91 .95 .94 .85
KLA/ATP 1.09 1.21 1.09 .97 1.00 .93 .95
Ets1
KLA  ATP  ATP+KLA
 NM_011808 E26 avian leukemia oncogene 1, 5 domain (Ets1), transcript variant 1, mRNA [NM_011808] KLA .55 .54 .49 .66 .62 .58 .67
ATP 1.01 1.14 .98 1.11 1.59 1.48 .67
KLA/ATP .58 .53 .58 .70 .80 .76 .76
Ets1
KLA  ATP  ATP+KLA
 X55787 gb|M.musculus c-ets-1 gene. [X55787] KLA .83 .93 .85 .89 .94 .90 1.03
ATP 1.08 1.11 .92 1.04 1.19 1.19 .98
KLA/ATP .94 .90 .88 .98 .91 .92 .95
Fh1
KLA  ATP  ATP+KLA
 NM_010209 fumarate hydratase 1 (Fh1), mRNA [NM_010209] KLA 1.00 .88 .79 .83 .55 .36 .39
ATP 1.05 1.05 1.08 .98 .89 .49 .45
KLA/ATP .91 .95 1.06 .92 .72 .41 .18
Flcn
KLA  ATP  ATP+KLA
 NM_146018 folliculin (Flcn), mRNA [NM_146018] KLA .16 .18 .22 .34 .53 .65 .73
ATP 1.01 .98 .77 1.26 2.69 .74 1.34
KLA/ATP .19 .18 .16 .58 2.65 1.30 1.00
Gab1
KLA  ATP  ATP+KLA
 NM_021356 growth factor receptor bound protein 2-associated protein 1 (Gab1), mRNA [NM_021356] KLA .83 .95 1.12 1.59 3.13 3.14 1.50
ATP .94 .96 1.12 1.74 2.35 5.20 1.66
KLA/ATP .79 .78 1.32 3.74 3.08 4.44 2.62
Grb2
KLA  ATP  ATP+KLA
 NM_008163 growth factor receptor bound protein 2 (Grb2), mRNA [NM_008163] KLA .92 .88 .90 1.27 1.43 1.22 1.00
ATP 1.02 .83 .51 .42 .92 .70 .57
KLA/ATP .84 .77 .61 .56 1.56 1.49 .52
Grb2
KLA  ATP  ATP+KLA
 U07617 Grb2 adaptor protein (grb2) mRNA, complete cds. [U07617] KLA .83 .80 .95 1.13 1.38 1.36 1.06
ATP .84 .74 .51 .41 .82 .74 .59
KLA/ATP .77 .70 .57 .54 1.49 1.39 .53
Hgf
KLA  ATP  ATP+KLA
 AK033274 15 days embryo male testis cDNA, RIKEN full-length enriched library, clone:8030481P22 product:inferred: hepatocyte growth factor [AK033274] KLA 1.34 1.22 .96 .93 .82 .93 .87
ATP 1.64 2.45 3.30 1.89 .97 1.12 .90
KLA/ATP 1.49 2.50 3.96 1.88 1.07 1.00 .83
Hgf
KLA  ATP  ATP+KLA
 NM_010427 hepatocyte growth factor (Hgf), mRNA [NM_010427] KLA 1.11 1.18 1.30 1.20 1.08 .96 1.14
ATP 1.02 1.14 1.32 1.62 1.17 1.26 1.47
KLA/ATP 1.18 1.24 1.33 1.84 1.19 1.09 1.31
Hif1a
KLA  ATP  ATP+KLA
 NM_010431 hypoxia inducible factor 1, alpha subunit (Hif1a), mRNA [NM_010431] KLA 2.52 2.50 2.52 1.78 1.87 1.39 1.96
ATP 1.16 1.37 1.11 1.44 2.11 4.46 1.97
KLA/ATP 2.76 2.92 1.75 2.60 2.39 4.75 5.37
Hras1
KLA  ATP  ATP+KLA
 NM_008284 Harvey rat sarcoma virus oncogene 1 (Hras1), mRNA [NM_008284] KLA .79 .82 .77 .82 .94 1.03 1.07
ATP 1.01 .95 .69 .83 .79 1.12 1.15
KLA/ATP .84 .77 .61 .65 .82 1.00 1.05
Jun
KLA  ATP  ATP+KLA
 NM_010591 Jun oncogene (Jun), mRNA [NM_010591] KLA 1.08 .96 1.09 1.09 .75 .88 .81
ATP 1.26 1.48 4.45 8.73 4.02 1.16 1.99
KLA/ATP 1.12 1.38 3.52 5.17 3.32 .49 1.42
Kras
KLA  ATP  ATP+KLA
 NM_021284 v-Ki-ras2 Kirsten rat sarcoma viral oncogene homolog (Kras), mRNA [NM_021284] KLA .53 .49 .40 .42 .49 .95 1.05
ATP .98 1.01 1.16 1.17 1.39 1.29 1.74
KLA/ATP .50 .47 .50 .56 1.00 1.24 1.58
Map2k1
KLA  ATP  ATP+KLA
 NM_008927 mitogen-activated protein kinase kinase 1 (Map2k1), mRNA [NM_008927] KLA 1.82 2.00 2.31 2.03 2.51 2.20 1.51
ATP .99 1.14 .81 .87 .90 1.57 1.11
KLA/ATP 1.90 2.03 1.50 1.93 1.63 2.03 2.06
Map2k2
KLA  ATP  ATP+KLA
 NM_023138 mitogen-activated protein kinase kinase 2 (Map2k2), mRNA [NM_023138] KLA .96 1.01 1.09 .99 1.11 1.15 1.42
ATP 1.07 1.05 .74 .86 1.04 1.16 1.21
KLA/ATP 1.14 1.03 .68 .78 .85 1.01 1.20
Mapk1
KLA  ATP  ATP+KLA
 NM_001038663 mitogen-activated protein kinase 1 (Mapk1), transcript variant 2, mRNA [NM_001038663] KLA .97 1.03 .93 .86 .79 1.01 1.04
ATP .96 1.18 1.01 1.13 .84 1.04 1.16
KLA/ATP .99 .99 .84 .87 .63 .96 1.26
Mapk1
KLA  ATP  ATP+KLA
 NM_011949 mitogen-activated protein kinase 1 (Mapk1), transcript variant 1, mRNA [NM_011949] KLA .88 .80 .80 .73 .75 .76 .65
ATP .97 .96 1.06 .88 .90 .68 .48
KLA/ATP .82 .81 .78 .65 .64 .64 .45
Mapk3
KLA  ATP  ATP+KLA
 NM_011952 mitogen-activated protein kinase 3 (Mapk3), mRNA [NM_011952] KLA .81 .85 .88 .72 .79 .73 .90
ATP 1.13 1.30 .92 1.48 1.08 .68 1.03
KLA/ATP 1.01 1.01 .66 1.13 .77 .77 1.16
Met
KLA  ATP  ATP+KLA
 NM_008591 met proto-oncogene (Met), mRNA [NM_008591] KLA 3.56 3.71 3.68 3.79 4.24 5.89 6.95
ATP .98 .96 1.16 1.21 3.32 12.98 6.60
KLA/ATP 3.75 3.80 3.58 3.28 3.69 4.27 14.22
Mm.13157
2
KLA  ATP  ATP+KLA
 134949023 Unknown KLA 1.04 1.01 .96 .95 .95 1.00 .99
ATP .98 1.02 .99 1.07 .97 .96 1.00
KLA/ATP .96 .88 .91 1.00 1.02 .98 1.05
Mm.21312
8
KLA  ATP  ATP+KLA
 141801344 Unknown KLA .96 .95 .83 .77 .52 .99 1.32
ATP .80 .82 1.09 .80 .83 1.19 1.46
KLA/ATP .78 .92 .98 .62 .71 .94 1.41
Mm.22094
6
KLA  ATP  ATP+KLA
 27545180 Unknown KLA 1.00 .93 .97 1.05 1.06 1.29 1.13
ATP .90 .94 1.25 1.18 .85 .62 1.20
KLA/ATP .86 .99 1.14 .99 .83 .70 1.26
Mm.24185
7
KLA  ATP  ATP+KLA
 142347489 Unknown KLA 1.18 1.09 1.27 1.24 1.14 1.18 1.15
ATP 1.10 1.02 1.13 1.16 1.04 1.03 1.11
KLA/ATP 1.17 1.19 1.29 1.21 1.10 1.02 1.19
Mm.25381
9
KLA  ATP  ATP+KLA
 118130676 Unknown KLA 1.81 1.88 1.96 1.62 1.89 2.44 1.56
ATP .92 .91 1.24 1.01 1.16 2.06 1.95
KLA/ATP 1.62 1.86 1.86 1.41 1.89 2.37 1.97
Mm.28924
8
KLA  ATP  ATP+KLA
 148747277 Unknown KLA 1.36 1.32 1.33 1.38 1.29 1.32 .98
ATP .86 .92 1.42 1.26 1.10 .95 .57
KLA/ATP 1.16 1.34 1.72 1.53 1.42 .87 .61
Nras
KLA  ATP  ATP+KLA
 NM_010937 neuroblastoma ras oncogene (Nras), mRNA [NM_010937] KLA 1.20 1.22 1.27 1.20 1.09 .91 .84
ATP .98 .91 .69 .61 .59 .67 .78
KLA/ATP 1.22 1.14 .97 .79 .73 .61 .72
Pak1
KLA  ATP  ATP+KLA
 NM_011035 p21 (CDKN1A)-activated kinase 1 (Pak1), mRNA [NM_011035] KLA .72 .77 .79 .71 .67 .73 .95
ATP 1.10 1.07 .99 1.15 1.27 .62 .51
KLA/ATP .85 .83 .73 .76 .76 .55 .33
Pak2
KLA  ATP  ATP+KLA
 NM_177326 p21 (CDKN1A)-activated kinase 2 (Pak2), mRNA [NM_177326] KLA 1.23 1.24 1.26 1.17 1.19 1.09 1.13
ATP 1.04 1.01 .65 .58 .82 1.18 1.45
KLA/ATP 1.26 1.26 .78 .72 .71 .95 1.44
Pak3
KLA  ATP  ATP+KLA
 NM_008778 p21 (CDKN1A)-activated kinase 3 (Pak3), mRNA [NM_008778] KLA 1.06 1.02 1.03 1.00 1.06 1.01 1.01
ATP 1.05 1.01 1.03 .97 .98 1.08 1.07
KLA/ATP 1.00 .99 .99 1.03 1.00 1.01 1.08
Pak4
KLA  ATP  ATP+KLA
 NM_027470 p21 (CDKN1A)-activated kinase 4 (Pak4), mRNA [NM_027470] KLA 1.41 1.51 1.62 1.57 1.88 1.26 1.06
ATP 1.13 1.15 1.04 1.21 1.73 1.45 1.03
KLA/ATP 1.58 1.60 1.31 1.65 1.84 1.64 1.40
Pak6
KLA  ATP  ATP+KLA
 AK028788 10 days neonate skin cDNA, RIKEN full-length enriched library, clone:4732456M09 product:p21 (CDKN1A)-activated kinase 6, full insert sequence. [AK028788] KLA 1.38 1.33 1.40 1.45 1.42 1.49 1.20
ATP .95 .93 1.15 1.21 1.21 1.32 1.10
KLA/ATP 1.33 1.38 1.55 1.44 1.57 1.45 1.36
Pak7
KLA  ATP  ATP+KLA
 AK077967 13 days embryo male testis cDNA, RIKEN full-length enriched library, clone:6030481C12 product:hypothetical protein, full insert sequence. [AK077967] KLA 1.00 1.01 1.07 1.02 .99 1.01 1.05
ATP .93 .95 1.03 1.01 1.02 .92 1.00
KLA/ATP 1.04 1.01 .99 1.04 .99 1.06 1.02
Pdgfa
KLA  ATP  ATP+KLA
 NM_008808 platelet derived growth factor, alpha (Pdgfa), mRNA [NM_008808] KLA .63 .56 .42 .34 .31 .33 .52
ATP .89 .80 .69 1.23 5.97 3.99 2.73
KLA/ATP .64 .53 .43 .77 3.48 3.78 2.37
Pdgfb
KLA  ATP  ATP+KLA
 NM_011057 platelet derived growth factor, B polypeptide (Pdgfb), mRNA [NM_011057] KLA .45 .43 .38 .46 .69 .48 .58
ATP .94 .95 .66 .74 .67 .77 1.06
KLA/ATP .43 .43 .37 .39 .52 .55 1.64
Pik3ca
KLA  ATP  ATP+KLA
 ENSMUST00000108243 ens|Phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha isoform (EC 2.7.1.153) (PI3-kinase p110 subunit alpha) (PtdIns-3- kinase p110) (PI3K). [Source:Uniprot/SWISSPROT;Acc:P42337] [ENSMUST00000108243] KLA 1.07 1.01 .91 .90 .98 .96 .86
ATP 1.03 .87 1.12 .63 1.22 1.86 .60
KLA/ATP 1.05 .82 .91 .61 1.17 1.26 .63
Pik3ca
KLA  ATP  ATP+KLA
 NM_008839 phosphatidylinositol 3-kinase, catalytic, alpha polypeptide (Pik3ca), mRNA [NM_008839] KLA 1.15 1.11 1.05 .82 .99 1.03 1.27
ATP .98 1.00 .79 .75 .96 1.32 1.10
KLA/ATP 1.10 .98 .64 .72 .80 1.20 1.41
Pik3cb
KLA  ATP  ATP+KLA
 NM_029094 phosphatidylinositol 3-kinase, catalytic, beta polypeptide (Pik3cb), mRNA [NM_029094] KLA 1.06 1.06 1.03 .73 .68 .98 1.69
ATP 1.04 1.21 .95 1.02 .85 .93 1.73
KLA/ATP 1.15 1.27 .73 .83 .58 .81 1.81
Pik3cd
KLA  ATP  ATP+KLA
 NM_008840 phosphatidylinositol 3-kinase catalytic delta polypeptide (Pik3cd), transcript variant 1, mRNA [NM_008840] KLA 2.28 2.42 3.10 4.17 3.35 2.31 1.34
ATP 1.02 .91 .99 .63 .30 .67 .80
KLA/ATP 2.14 2.23 2.70 1.51 1.17 .85 .72
Pik3cd
KLA  ATP  ATP+KLA
 U86587 phosphatidylinositol 3-kinase catalytic subunit p110 delta mRNA, complete cds. [U86587] KLA 2.21 2.24 3.71 3.17 3.67 2.66 1.48
ATP 1.00 1.03 .93 .96 .46 .75 .97
KLA/ATP 2.27 2.32 1.97 2.02 1.01 .99 .98
Pik3cg
KLA  ATP  ATP+KLA
 NM_020272 phosphoinositide-3-kinase, catalytic, gamma polypeptide (Pik3cg), mRNA [NM_020272] KLA .53 .53 .61 .64 .97 .86 .79
ATP 1.01 1.13 .88 .89 .52 .53 .53
KLA/ATP .58 .53 .43 .60 .40 .43 .62
Pik3r1
KLA  ATP  ATP+KLA
 NM_001077495 phosphatidylinositol 3-kinase, regulatory subunit, polypeptide 1 (p85 alpha) (Pik3r1), transcript variant 2, mRNA [NM_001077495] KLA 1.05 1.07 1.03 1.00 1.01 1.20 .85
ATP .97 1.02 1.48 1.42 1.76 1.33 1.23
KLA/ATP 1.11 1.12 1.06 1.17 1.24 .99 1.12
Pik3r2
KLA  ATP  ATP+KLA
 NM_008841 phosphatidylinositol 3-kinase, regulatory subunit, polypeptide 2 (p85 beta) (Pik3r2), mRNA [NM_008841] KLA .50 .50 .48 .43 .46 .66 .75
ATP .78 .68 .45 .43 .28 .57 1.37
KLA/ATP .49 .38 .32 .33 .38 .67 1.10
Pik3r3
KLA  ATP  ATP+KLA
 NM_181585 phosphatidylinositol 3 kinase, regulatory subunit, polypeptide 3 (p55) (Pik3r3), mRNA [NM_181585] KLA 1.59 1.49 1.37 1.17 1.05 1.55 1.41
ATP 1.12 1.00 1.33 1.70 2.01 2.37 2.02
KLA/ATP 1.63 1.54 1.58 1.70 2.43 2.68 1.92
Pik3r5
KLA  ATP  ATP+KLA
 NM_177320 phosphoinositide-3-kinase, regulatory subunit 5, p101 (Pik3r5), mRNA [NM_177320] KLA 3.57 3.58 4.16 3.54 4.11 2.59 2.39
ATP 1.08 1.08 .93 1.67 3.11 1.88 1.34
KLA/ATP 3.91 3.70 3.30 3.80 2.70 2.04 3.00
Ptpn11
KLA  ATP  ATP+KLA
 NM_001109992 protein tyrosine phosphatase, non-receptor type 11 (Ptpn11), transcript variant 2, mRNA [NM_001109992] KLA 1.52 1.71 1.59 1.78 1.62 1.57 1.35
ATP 1.04 .93 .86 .79 1.09 1.95 1.90
KLA/ATP 1.59 1.61 1.45 1.11 1.18 1.82 3.02
Ptpn11
KLA  ATP  ATP+KLA
 NM_011202 protein tyrosine phosphatase, non-receptor type 11 (Ptpn11), transcript variant 1, mRNA [NM_011202] KLA 1.32 1.28 1.17 1.21 1.18 1.06 1.05
ATP .97 .77 .71 .56 .90 1.27 1.04
KLA/ATP 1.22 1.21 1.02 .70 .96 1.06 .94
Rac1
KLA  ATP  ATP+KLA
 NM_009007 RAS-related C3 botulinum substrate 1 (Rac1), mRNA [NM_009007] KLA 1.02 1.01 1.02 .99 1.03 1.15 1.08
ATP .99 1.15 1.01 1.27 1.06 1.20 1.06
KLA/ATP 1.00 1.04 .88 1.16 .91 1.21 1.38
Raf1
KLA  ATP  ATP+KLA
 AK036317 16 days neonate cerebellum cDNA, RIKEN full-length enriched library, clone:9630056E02 product:v-raf-1 leukemia viral oncogene 1, full insert sequence. [AK036317] KLA 1.47 1.34 1.55 1.29 1.59 1.32 1.46
ATP 1.05 .98 .54 .63 3.32 2.07 1.01
KLA/ATP 1.57 1.33 .79 .96 2.26 1.38 1.35
Raf1
KLA  ATP  ATP+KLA
 NM_029780 v-raf-leukemia viral oncogene 1 (Raf1), mRNA [NM_029780] KLA 1.65 1.64 1.93 1.77 1.77 1.72 1.81
ATP .95 .96 .83 .80 2.22 2.92 1.19
KLA/ATP 1.68 1.64 1.39 1.32 1.85 2.50 2.06
Rap1a
KLA  ATP  ATP+KLA
 AK030897 adult male thymus cDNA, RIKEN full-length enriched library, clone:5830450G12 product:RAS-related protein-1a, full insert sequence [AK030897] KLA .83 .80 .92 1.04 1.06 .91 1.06
ATP 1.04 .92 1.11 1.03 1.05 .73 .72
KLA/ATP .83 .81 .97 .75 1.14 .71 .53
Rap1a
KLA  ATP  ATP+KLA
 NM_145541 RAS-related protein-1a (Rap1a), mRNA [NM_145541] KLA .87 .78 .76 .86 .86 .84 1.01
ATP .91 .95 1.33 1.20 1.27 1.04 .81
KLA/ATP .68 .75 .92 .85 1.13 .90 .74
Rap1b
KLA  ATP  ATP+KLA
 M79314 GTP-binding protein RAP1b mRNA, partial cds. [M79314] KLA 2.61 2.95 2.81 2.76 3.07 2.67 1.88
ATP 1.00 1.10 1.00 1.94 1.94 1.72 1.31
KLA/ATP 2.49 2.45 2.03 4.23 3.03 2.60 1.86
Rap1b
KLA  ATP  ATP+KLA
 NM_024457 RAS related protein 1b (Rap1b), mRNA [NM_024457] KLA 2.21 2.35 2.71 2.51 2.86 2.44 1.54
ATP 1.05 .92 .93 1.14 1.30 1.26 1.07
KLA/ATP 2.23 2.15 1.57 2.53 2.16 1.67 1.38
Rapgef1
KLA  ATP  ATP+KLA
 NM_001039087 Rap guanine nucleotide exchange factor (GEF) 1 (Rapgef1), transcript variant 1, mRNA [NM_001039087] KLA .93 .89 .88 .67 .73 .90 1.16
ATP 1.12 1.09 .82 1.25 1.43 1.63 1.58
KLA/ATP 1.03 .95 .67 .74 .65 .89 1.77
Rbx1
KLA  ATP  ATP+KLA
 NM_019712 ring-box 1 (Rbx1), mRNA [NM_019712] KLA 1.04 1.01 .98 1.09 1.06 1.14 1.09
ATP .92 .89 1.13 1.16 1.68 1.07 .83
KLA/ATP .99 .99 1.25 1.31 2.63 2.06 .67
Slc2a1
KLA  ATP  ATP+KLA
 NM_011400 solute carrier family 2 (facilitated glucose transporter), member 1 (Slc2a1), mRNA [NM_011400] KLA 1.31 1.46 1.10 1.68 1.75 1.95 2.34
ATP .88 .90 1.32 1.99 3.40 10.49 1.93
KLA/ATP 1.13 1.25 1.71 2.14 3.71 6.31 4.63
Sos1
KLA  ATP  ATP+KLA
 NM_009231 Son of sevenless homolog 1 (Drosophila) (Sos1), mRNA [NM_009231] KLA 2.36 2.40 3.42 3.15 2.78 1.81 1.71
ATP .99 1.00 .99 1.15 1.14 1.25 1.24
KLA/ATP 2.41 2.26 1.95 2.44 1.47 1.66 1.37
Sos2
KLA  ATP  ATP+KLA
 XM_127051 gb|PREDICTED: Mus musculus Son of sevenless homolog 2 (Drosophila) (Sos2), mRNA [XM_127051] KLA .81 .77 .79 .92 1.04 1.06 1.20
ATP 1.00 1.00 1.09 .79 .68 .81 .94
KLA/ATP .77 .69 .71 .60 .64 .77 1.07
Tceb1
KLA  ATP  ATP+KLA
 NM_026456 transcription elongation factor B (SIII), polypeptide 1 (Tceb1), mRNA [NM_026456] KLA 1.27 1.21 1.25 1.65 1.46 1.21 1.26
ATP 1.11 1.01 1.44 1.34 1.46 1.17 .74
KLA/ATP 1.20 1.48 2.16 1.77 1.56 1.13 .89
Tceb2
KLA  ATP  ATP+KLA
 NM_026305 transcription elongation factor B (SIII), polypeptide 2 (Tceb2), mRNA [NM_026305] KLA .99 1.00 .96 1.01 1.04 .96 1.24
ATP 1.15 1.17 1.03 1.36 1.25 1.05 1.27
KLA/ATP 1.07 1.13 1.08 1.30 1.21 1.23 1.56
Tgfa
KLA  ATP  ATP+KLA
 NM_031199 transforming growth factor alpha (Tgfa), mRNA [NM_031199] KLA 1.01 .99 1.00 1.03 1.01 1.04 1.04
ATP 1.01 1.04 1.02 1.02 1.02 1.01 1.05
KLA/ATP 1.01 1.02 1.02 1.02 1.02 1.06 1.02
Tgfb1
KLA  ATP  ATP+KLA
 NM_011577 transforming growth factor, beta 1 (Tgfb1), mRNA [NM_011577] KLA .87 .89 .90 .70 .83 .77 1.12
ATP 1.20 1.41 .80 1.49 1.11 .93 .99
KLA/ATP 1.10 1.20 .53 1.05 .66 .85 .90
Tgfb2
KLA  ATP  ATP+KLA
 NM_009367 transforming growth factor, beta 2 (Tgfb2), mRNA [NM_009367] KLA 1.01 .91 .98 .98 .92 1.19 .96
ATP .99 1.03 1.00 1.02 .99 1.07 .93
KLA/ATP 1.02 .99 1.03 .98 1.04 1.06 .96
Tgfb3
KLA  ATP  ATP+KLA
 NM_009368 transforming growth factor, beta 3 (Tgfb3), mRNA [NM_009368] KLA .67 .64 .58 .56 .49 .52 .61
ATP .90 .92 1.33 1.08 .78 .65 .74
KLA/ATP .58 .60 .74 .61 .76 1.36 1.51
Vegfa
KLA  ATP  ATP+KLA
 NM_001025250 vascular endothelial growth factor A (Vegfa), transcript variant 1, mRNA [NM_001025250] KLA .49 .48 .46 .46 .39 .64 1.18
ATP 1.05 1.37 3.82 10.55 12.51 24.20 7.85
KLA/ATP .48 .59 1.45 7.42 19.75 27.42 22.35
Vegfa
KLA  ATP  ATP+KLA
 NM_001025257 vascular endothelial growth factor A (Vegfa), transcript variant 3, mRNA [NM_001025257] KLA .72 .71 .66 .70 .65 .80 1.22
ATP 1.01 1.21 3.24 11.12 11.09 18.59 5.43
KLA/ATP .68 .71 1.47 5.94 15.06 20.32 17.31
Vhlh
KLA  ATP  ATP+KLA
 S76748 gb|mVHLh1=von Hippel-Lindau disease gene [mice, mRNA, 2757 nt]. [S76748] KLA 1.39 1.39 1.47 1.46 1.62 1.84 1.48
ATP .73 .64 .54 .55 1.44 2.26 1.44
KLA/ATP 1.17 1.13 .91 .73 1.72 2.26 2.16